JP2018533582A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533582A5
JP2018533582A5 JP2018522126A JP2018522126A JP2018533582A5 JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5 JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018533582 A5 JP2018533582 A5 JP 2018533582A5
Authority
JP
Japan
Prior art keywords
cancer
use according
pharmaceutically acceptable
acceptable salt
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522126A
Other languages
English (en)
Japanese (ja)
Other versions
JP6833844B2 (ja
JP2018533582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059342 external-priority patent/WO2017075363A1/en
Publication of JP2018533582A publication Critical patent/JP2018533582A/ja
Publication of JP2018533582A5 publication Critical patent/JP2018533582A5/ja
Application granted granted Critical
Publication of JP6833844B2 publication Critical patent/JP6833844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522126A 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法 Active JP6833844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021014795A Division JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018533582A JP2018533582A (ja) 2018-11-15
JP2018533582A5 true JP2018533582A5 (enExample) 2020-03-19
JP6833844B2 JP6833844B2 (ja) 2021-02-24

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522126A Active JP6833844B2 (ja) 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Country Status (36)

Country Link
US (4) US10065974B2 (enExample)
EP (3) EP3693375B1 (enExample)
JP (3) JP6833844B2 (enExample)
KR (2) KR20220118559A (enExample)
CN (4) CN113201002A (enExample)
AU (3) AU2016343656B2 (enExample)
BR (3) BR122020022280B1 (enExample)
CA (1) CA3003271A1 (enExample)
CL (4) CL2018001134A1 (enExample)
CO (1) CO2018004750A2 (enExample)
CR (3) CR20210389A (enExample)
CY (1) CY1123557T1 (enExample)
DK (2) DK3368541T3 (enExample)
EA (1) EA038276B1 (enExample)
EC (1) ECSP18040250A (enExample)
ES (3) ES2910928T3 (enExample)
HR (1) HRP20201046T1 (enExample)
HU (1) HUE054972T2 (enExample)
IL (3) IL258731B (enExample)
LT (1) LT3368541T (enExample)
MA (2) MA50636A (enExample)
MD (1) MD3368541T2 (enExample)
MX (1) MX2018005294A (enExample)
MY (1) MY201783A (enExample)
NZ (1) NZ742742A (enExample)
PH (2) PH12022551082A1 (enExample)
PL (1) PL3368541T3 (enExample)
PT (1) PT3368541T (enExample)
RS (1) RS60695B1 (enExample)
SG (4) SG10201911402YA (enExample)
SI (1) SI3368541T1 (enExample)
SM (1) SMT202000469T1 (enExample)
TW (3) TWI710565B (enExample)
UA (1) UA125289C2 (enExample)
WO (1) WO2017075363A1 (enExample)
ZA (4) ZA201803556B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
EP3842442B1 (en) 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
US11655260B2 (en) 2017-12-22 2023-05-23 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US12054500B2 (en) 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020102646A2 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020131598A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US20220251116A1 (en) * 2019-02-06 2022-08-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
US11420966B2 (en) * 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
JP7579324B2 (ja) * 2019-07-23 2024-11-07 アストラゼネカ・アクチエボラーグ アルギナーゼ阻害剤及びその使用方法
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
WO2021141751A1 (en) * 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
WO2022016195A1 (en) 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
KR20250169642A (ko) 2023-03-13 2025-12-03 인사이트 코포레이션 키나제 억제제로서의 이환식 우레아
WO2026076207A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE602004023516D1 (de) 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
WO2009008415A1 (ja) 2007-07-12 2009-01-15 Sanyo Denki Co., Ltd. 二重反転式軸流送風機
EP2214660A2 (en) * 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
TR201910726T4 (tr) * 2009-01-26 2019-08-21 Astrazeneca Uk Ltd Arginaz inhibitörleri ve kullanım yöntemleri.
BR112012027034B1 (pt) 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
IN2014DN09678A (enExample) 2012-04-18 2015-07-31 Mars Inc
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
TWI617309B (zh) * 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
EP3270907A1 (en) 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Similar Documents

Publication Publication Date Title
HRP20201046T1 (hr) Sastavi i metode za inhibitivnu aktivnost arginase
IL292677A (en) Preparations and methods for inhibiting arginase activity
JP2020514271A5 (enExample)
JP6382831B2 (ja) アポトーシス阻害タンパク質(iap)のアンタゴニスト
TWI826416B (zh) 趨化介素受體調節劑及其用途
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
ES2821790T3 (es) Moduladores de la vía de estrés integrada
KR102781404B1 (ko) 통합 스트레스 경로의 조정제
JP2023504286A5 (enExample)
EP2408300B1 (en) Amino ester derivatives, salts thereof and methods of use
ES2941790T3 (es) Copolímeros dibloque autoensamblados compuestos de PEGMEMA y segmentos poliméricos portadores de fármacos
JP7427655B2 (ja) 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
EP3802544A1 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
CN109689628A (zh) 整合应激通路的调节剂
JP2006507308A5 (enExample)
JP2020510032A5 (enExample)
JP2019194194A (ja) 癌を治療するためのhdac8阻害剤
KR20070010125A (ko) 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물
JP2020514344A5 (enExample)
JP2019524852A5 (enExample)
JP2025525869A (ja) フェロトーシスを誘導するための組成物および方法
JP2023501038A (ja) 新規の治療的使用
JP2019536783A5 (enExample)
CN105283456A (zh) 5-溴-靛玉红
US8937088B2 (en) Ureas for the treatment and prevention of cancer